SCHEMBL12598513

SCHEMBL12598513

Cc1ccc(S(=O)(=O)Nc2cccc3cc[nH]c23)cc1C(N)=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ MAPK1 P28482 1/20 0.57
▸ NR3C1 P04150 1/20 0.51
▸ PGR P06401 1/20 0.51
▸ NR3C2 P08235 1/20 0.51
▸ AR P10275 1/20 0.51
▸ PDPK1 O15530 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ IKBKB O14920 1/20 0.41
▸ CHUK O15111 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PTGES2 Q9H7Z7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367682 0.78 NR3C1 (0.64) SMN1; SMN2NR3C1PGRNR3C2AR
SCHEMBL12598516 0.78 SLC40A1 (0.64) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL1984869 0.76 CA1 (0.60) NR3C1PGRNR3C2ARMEN1
SCHEMBL1987233 0.75 GFER (0.61) SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3061760 0.75 NR3C1 (0.56) NR3C1PGRNR3C2ARHSD17B10
SCHEMBL3055215 0.74 NR3C1 (0.56) NR3C1PGRNR3C2ARALDH1A1
SCHEMBL2367383 0.74 NR3C1 (0.65) SMN1; SMN2NR3C1PGRNR3C2AR
SCHEMBL3066019 0.73 SLC40A1 (0.57) NR3C1PGRNR3C2ARPTGES2
SCHEMBL2367735 0.73 NR3C1 (0.60) NR3C1PGRNR3C2ARALDH1A1
SCHEMBL2403697 0.72 TUBB4A (0.61) NR3C1PGRNR3C2ARLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011072174-A1 THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION AGIOS PHARMACEUTICALS, INC. (US) 2011-06-16 — — WO disclosed
Send feedback